TABLE 1.

Analysis of cellular viability of MSCs treated with FAAH inhibitors, endocannabinoids, and endocannabinoid-like substances

Concentration (μM)	Viability (%)
	URB597	AA-5HT	AEA	2-AG	OEA	PEA
0	100.0 ± 1.2	100.0 ± 1.6	100.0 ± 4.0	100.0 ± 3.5	100.0 ± 3.6	100.0 ± 6.1
0.1	86.7 ± 1.7a	91.2 ± 3.2a	79.3 ± 7.6b	93.6 ± 9.7b	94.3 ± 4.9b	93.2 ± 6.3b
1	87.4 ± 1.6a	89.8 ± 2.9a	85.0 ± 7.8b	95.4 ± 7.9b	91.5 ± 5.1b	99.9 ± 5.6b
10	91.0 ± 1.6a	88.7 ± 2.5a	93.3 ± 3.7b	126.9 ± 9.0b	95.7 ± 5.1b	115.7 ± 4.3b

MSCs were treated with vehicle (line 0) or the indicated concentrations of test substances in serum-free DMEM for 6 h. Thereafter, viability was assessed by WST-1 test. Percent control represents mean ± SEM of n = 30 (URB597; five donors), n = 24 (AA-5HT; four donors), and n = 12 (AEA, 2-AG, OEA, and PEA; three donors) experiments.

^aP < 0.05 versus corresponding vehicle, one-way ANOVA plus post hoc Dunnett test.

^bNot significant versus corresponding vehicle, one-way ANOVA plus post hoc Dunnett test.